Skip to content
MarketScale
‹ Back to IndustriesSciences

For Wider Adoption of Small Modular Nuclear Reactors, Experts Call on Licensing & Permitting Reform

The future of scalable clean energy production is also the new dawn of nuclear with the advent of small modular nuclear reactors (SMRs), a promising technology capable of revolutionizing America’s and the world’s energy landscape. As the global push for greener energy sources intensifies, these reactors present a viable pathway towards achieving significant climate…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Nick Loris · C3 SolutionsColoradoNick LorisNuclear Energy
Share

Key takeaways

01

The future of scalable clean energy production is also the new dawn of nuclear with the advent of small modular nuclear reactors (SMRs), a promising technology capable of revolutionizing America’s and the world’s energy landscape.

02

As the global push for greener energy sources intensifies, these reactors present a viable pathway towards achieving significant climate…

The future of scalable clean energy production is also the new dawn of nuclear with the advent of small modular nuclear reactors (SMRs), a promising technology capable of revolutionizing America’s and the world’s energy landscape. As the global push for greener energy sources intensifies, these reactors present a viable pathway towards achieving significant climate and environmental goals. As more U.S. states invest research and resources into studying the potential benefits of mass nuclear energy deployment, what does the industry need to do to speed up the adoption process?

The global decarbonization drive is fueling a resurgence in nuclear energy, with Colorado now potentially following suit thanks to the newly passed “Assess Advanced Energy Solutions In Rural Colorado” bill. Despite facing opposition over safety, cost, and environmental issues, Colorado is taking its queues from clean energy experts, who say nuclear power is necessary for true carbon-free power generation, as it can provide large-scale, low-carbon electricity continuously. Meanwhile, the U.S. Department of Energy, under the Biden administration, is promoting advanced nuclear reactor projects, though cost and technological hurdles remain. Reflecting shifting attitudes towards nuclear power, California has reversed the scheduled shutdown of the Diablo Canyon nuclear power plant in response to power shortages.

Nick Loris, Vice President of Public Policy at C3 Solutions, delves deeper into the transformative potential of small modular reactors and the critical policy reforms needed for their wider adoption in the U.S.

Nick’s Thoughts

“Small modular nuclear reactors have tremendous potential to meet America and the world’s energy needs while also meeting key environmental and climate objectives. They also have tremendous potential to meet America and the world’s energy security needs by weaning Europe off Russian natural gas. And we’ve seen American companies already committing to building SMRs in Europe. What we need is more of that action here in the United States and the collaboration between the national laboratories and the private sector is exactly what you want to see to help get a number of these technologies off the ground and to de-risk them. There’s a lot of excitement from venture capitalists to entrepreneurs and innovators, as well as the general public for nuclear power as support for the technology is the highest it’s been in 10 years.

What we really need to see now though is licensing and permitting reform. For instance, the Nuclear Regulatory Commission’s just licensed and certified NuScale’s reactor design, but it took half a billion dollars in costs for the company to get through the process, not to mention they started that process in 2008. So if we want to have more of these innovative technologies reach the marketplace to provide durable emissions-free power, we need more efficient regulatory and permitting processes while still maintaining the necessary environmental safeguards to get these technologies off the ground.”

Article written by Daniel Litwin.

About the author

Nick Loris
Nick LorisVice President of Public Policy

You can write about your years of experience, industry, or skills. (Feel free to copy and paste your LinkedIn 'About' info here).

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics taps photonics veteran Neil Anderson as CRO to scale flat optics into AI datacenters and AR

Myrias Optics has hired Neil Anderson, Ph.D. as the Chief Revenue Officer to spearhead the commercialization of its nanoimprint flat optics platform. The platform is intended for use in AI datacenters, augmented reality (AR), and life sciences applications. Anderson's experience in photonics is expected to aid Myrias Optics in expanding its market presence in these sectors.

  • 01Myrias Optics appointed Neil Anderson, Ph.D. as CRO to lead the commercialization of its technology.
  • 02The company focuses on nanoimprint flat optics for AI datacenters, AR, and life sciences.
  • 03Neil Anderson brings extensive photonics expertise to support Myrias Optics' growth.

Jul 31, 2026

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Nick Loris
Nick Loris

Vice President of Public Policy

You can write about your years of experience, industry, or skills. (Feel free to copy and paste your LinkedIn 'About' info here).

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512